<DOC>
	<DOCNO>NCT01212302</DOCNO>
	<brief_summary>Dual antiplatelet therapy acetylsalicylic acid ( ASA , aspirin ) clopidogrel great importance treatment follow coronary stenting . Unfortunately variable platelet inhibitory effectiveness compromise antithrombotic benefit dual antiplatelet therapy . The aim prospective single centre study reduce low response incidence dual antiplatelet therapy ASA clopidogrel base standardized therapy algorithm .</brief_summary>
	<brief_title>Optimizing Aspirin Clopidogrel Therapy ( BOchum CLopidogrel Aspirin Plan )</brief_title>
	<detailed_description>Platelet function test use whole blood aggregometry perform 48 hour follow coronary stenting ( either acute coronary syndrome stable coronary artery disease ) . The antiplatelet therapy include load dose 600 mg clopidogrel 500 mg ASA , follow 75 mg clopidogrel 100 mg ASA daily . Clopidogrel low-response ( CLR ) and/or ASA ( ASA low response ) treat accord structure therapy plan .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Patients stable coronary artery disease ( CAD ) acute coronary syndrome ( ACS ) follow percutaneous coronary intervention ( PCI ) abnormal platelet count patient , severe liver disorder , current gastrointestinal disorder , current infection , congestive heart failure , know bleeding disorder , treatment bivalirudin glycoprotein IIb/IIIa antagonists within last 7 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Clopidogrel</keyword>
	<keyword>ASA</keyword>
	<keyword>Low Response</keyword>
	<keyword>Resistance</keyword>
</DOC>